Trial
NCT01738594
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
Amgen
Condition
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Intervention
carfilzomib
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-08-29